Journal
MOLECULAR THERAPY
Volume 5, Issue 6, Pages 695-704Publisher
CELL PRESS
DOI: 10.1006/mthe.2002.0599
Keywords
cancer; gene therapy; ovarian cancer; adenovirus; pseudotyping; toxicity; biodistribution
Categories
Funding
- NCI NIH HHS [R01 CA74242, P50 CA83591, R01 CA68245, R01 CA86881, R01 CA83821, CO97110, R01 CA90547-01, P50 CA89019] Funding Source: Medline
- NHLBI NIH HHS [R01 HL67962] Funding Source: Medline
Ask authors/readers for more resources
Adenovirus serotype 5 (Ad5) displays unparalleled gene transfer efficacy to cells with high coxsackie-adenovirus receptor (CAR) expression. Unfortunately, cells isolated from clinical human cancers, both ovarian and other types, express highly variable and often low levels of CAR. Fortunately, native Ads tropism can be modified to circumvent CAR deficiency and to enhance infectivity. Ad5/3luc1 incorporates the serotype 3 fiber knob and binds to a receptor distinct from CAR, while the fiber of Ad5lucRGD is modified with an RGD-4C motif, allowing CAR-independent binding to integrins. We studied the liver tropism and blood clearance of these viruses after intravenous (i.v.) injection, and biodistribution after intraperitoneal (i.p.) injection to tumor-bearing mice. To estimate efficacy, we assessed gene transfer to purified human primary ovarian cancer cells, and in a mouse model of ovarian cancer. Ad5/3luc1 achieved improved gene transfer over Ad5lucRGD, and both infectivity-enhanced viruses were superior to the isogenic control with an unmodified Ads capsid. In the presence of malignant ascites, gene transfer was improved with both Ad5/3luc1 and Ad5lucRGD. Thus, retargeting to the Ad3 receptor enhances gene transfer to clinically relevant ovarian cancer substrates, while the mouse toxicity and biodistribution profile of both fiber-modified Ad vectors is comparable to Ads.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available